 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...463464465466467468469470471472473...522523» |
- | oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial withdrawal, Metastases: Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) - Apr 19, 2018
P3, N=0, Withdrawn, Sponsor: Shanghai Zhongshan Hospital
N=98 --> 0 | Completed --> Withdrawn
- Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov) - Apr 19, 2018
P2, N=50, Recruiting, Sponsor: Virginia Commonwealth University
N=98 --> 0 | Completed --> Withdrawn Trial completion date: Dec 2018 --> Dec 2028 | Trial primary completion date: Dec 2018 --> Dec 2028
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment open, Metastases: STRADA: Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor (clinicaltrials.gov) - Apr 19, 2018
P2, N=50, Recruiting, Sponsor: Italian Sarcoma Group
Trial completion date: Dec 2018 --> Dec 2028 | Trial primary completion date: Dec 2018 --> Dec 2028 Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Enrollment open: Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=100, Recruiting, Sponsor: Fan Weijun
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bortezomib with Gemcitabine/Doxorubicin in Patients with Urothelial Cancer and Other Solid Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial completion date, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Apr 17, 2018
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Jun 2017 --> Dec 2018
- || Ninlaro (ixazomib) / Takeda
Trial completion date, Combination therapy, Surgery, Metastases: Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 17, 2018
P2, N=57, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2017 --> Dec 2018 Trial completion date: Jul 2021 --> Jul 2022
- Lartruvo (olaratumab) / Eli Lilly
Trial completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Apr 17, 2018
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jul 2021 --> Jul 2022 Trial completion date: Mar 2018 --> Sep 2018
- Lartruvo (olaratumab) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 17, 2018
P1b, N=40, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Mar 2018 --> Sep 2018 Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Jun 2018
- |||||||||| Tecentriq (atezolizumab) / Roche
New P3 trial, Combination therapy: IMpassion030: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 17, 2018
P3, N=2300, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | letrozole / Generic mfg.
New P2 trial: NeoChAI: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (clinicaltrials.gov) - Apr 12, 2018
P2, N=114, Recruiting, Sponsor: National Cancer Center, Korea
- | Trial completion date, Trial primary completion date, Metastases: ISG/AIEOP EW-1: Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma (clinicaltrials.gov) - Apr 11, 2018
P3, N=220, Recruiting, Sponsor: Italian Sarcoma Group
Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Jun 2018 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche
New P3 trial, Combination therapy: FeDeriCa: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (clinicaltrials.gov) - Apr 10, 2018
P3, N=500, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 9, 2018
P1, N=10, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Apr 6, 2018
P2, N=18, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- CBT-1 (tetrandrine) / CBA Pharma
Enrollment open, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Apr 6, 2018
P1, N=46, Recruiting, Sponsor: CBA Research
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- | Imfinzi (durvalumab) / AstraZeneca, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2018
P2, N=46, Active, not recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=120 --> 46
- | Rituxan (rituximab) / Roche
Enrollment change: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2018
P2, N=194, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=120 --> 46 N=38 --> 194
- Ninlaro (ixazomib) / Takeda
Trial completion date, Trial primary completion date: Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - Apr 5, 2018
P1, N=28, Recruiting, Sponsor: Massachusetts General Hospital
N=38 --> 194 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Mar 2018 --> Mar 2019
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment change, FDG PET, Metastases: S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - Apr 4, 2018
P2, N=371, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Mar 2018 --> Mar 2019 N=230 --> 371
- ||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial, Combination therapy: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 3, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || Iclusig (ponatinib) / Takeda, Otsuka
Trial completion date, Trial primary completion date: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 3, 2018
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=230 --> 371 Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2020
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Trial primary completion date, FDG PET: Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients (clinicaltrials.gov) - Apr 3, 2018
P=N/A, N=130, Recruiting, Sponsor: The Catholic University of Korea
Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2020 Trial completion date: Mar 2016 --> Dec 2020 | Trial primary completion date: Mar 2014 --> Dec 2018
- | Enrollment open, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Apr 3, 2018
P2, N=26, Recruiting, Sponsor: University of Miami
Trial completion date: Mar 2016 --> Dec 2020 | Trial primary completion date: Mar 2014 --> Dec 2018 Active, not recruiting --> Recruiting
- ||||| Anruixi (zuberitamab) / Zhejiang Hisun
New P2 trial: RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 2, 2018
P2, N=137, Completed, Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide (clinicaltrials.gov) - Mar 30, 2018
P4, N=18, Recruiting, Sponsor: Texas Tech University Health Sciences Center
Active, not recruiting --> Recruiting Trial primary completion date: Feb 2018 --> Sep 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion date, Trial primary completion date, Metastases: FOLL12: Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma (clinicaltrials.gov) - Mar 30, 2018
P3, N=810, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Trial primary completion date: Feb 2018 --> Sep 2018 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Kinenza (enzastaurin) / Denovo, Aytu BioPharma
Biomarker, Enrollment open: Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 (clinicaltrials.gov) - Mar 29, 2018
P3, N=235, Recruiting, Sponsor: Denovo Biopharma LLC
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound (clinicaltrials.gov) - Mar 27, 2018
P=N/A, N=10, Recruiting, Sponsor: InSightec
Not yet recruiting --> Recruiting Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer. (clinicaltrials.gov) - Mar 27, 2018
P=N/A, N=30, Recruiting, Sponsor: Johns Hopkins University
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018
- | doxorubicin hydrochloride / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date: Myocardial Perfusion and Fibrosis in Cancer Survivors (clinicaltrials.gov) - Mar 27, 2018
P, N=16, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018 Phase classification: P=N/A --> P | Trial completion date: Jun 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Dec 2018
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date: LCCC1637: BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (clinicaltrials.gov) - Mar 27, 2018
P2, N=28, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P=N/A --> P | Trial completion date: Jun 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Dec 2018 Trial completion date: May 2025 --> Jan 2026 | Trial primary completion date: May 2020 --> Jan 2021
- | New P3 trial: R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) (clinicaltrials.gov) - Mar 27, 2018
P3, N=80, Recruiting, Sponsor: Elena N.Parovichnikova
- || Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 26, 2018
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2025 --> Jan 2026 | Trial primary completion date: May 2020 --> Jan 2021 Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Apr 2020
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Mar 26, 2018
P1, N=45, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Apr 2020 Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Herceptin (trastuzumab) / Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab (clinicaltrials.gov) - Mar 23, 2018
P=N/A, N=26, Completed, Sponsor: Mayo Clinic
Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2018 Enrolling by invitation --> Completed | N=20 --> 26 | Trial completion date: Sep 2015 --> Jun 2017 | Trial primary completion date: Sep 2015 --> Jun 2017
- |||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: MEDISARC: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 23, 2018
P2, N=100, Recruiting, Sponsor: AIO-Studien-gGmbH
Enrolling by invitation --> Completed | N=20 --> 26 | Trial completion date: Sep 2015 --> Jun 2017 | Trial primary completion date: Sep 2015 --> Jun 2017 Not yet recruiting --> Recruiting
- ||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial completion, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Mar 22, 2018
P3, N=1418, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | lenalidomide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Trial completion, Metastases: AVD-Rev: Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients (clinicaltrials.gov) - Mar 22, 2018
P1, N=30, Completed, Sponsor: University of Cologne
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | epirubicin / Generic mfg.
Trial completion: NMIBCIVT: Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 22, 2018
P4, N=240, Completed, Sponsor: Mansoura University
Active, not recruiting --> Completed Recruiting --> Completed
- | thioguanine / Generic mfg.
Enrollment closed: AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 21, 2018
P3, N=9022, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Recruiting --> Active, not recruiting
- | sorafenib / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Sorafenib Chemoembolization Evaluation Controlled Trial (clinicaltrials.gov) - Mar 21, 2018
P2/3, N=246, Recruiting, Sponsor: Fourth Military Medical University
Recruiting --> Active, not recruiting Trial completion date: Jun 2016 --> Dec 2018 | Trial primary completion date: Mar 2016 --> Sep 2018
- | Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Mar 21, 2018
P2, N=6, Active, not recruiting, Sponsor: University of Miami
Trial completion date: Jun 2016 --> Dec 2018 | Trial primary completion date: Mar 2016 --> Sep 2018 Trial completion date: Apr 2019 --> Jun 2021 | Trial primary completion date: Mar 2017 --> Jun 2020
- || Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib (clinicaltrials.gov) - Mar 21, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Apr 2019 --> Jun 2021 | Trial primary completion date: Mar 2017 --> Jun 2020 Trial completion date: Mar 2023 --> Mar 2024
- ||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, PD(L)-1 Biomarker: Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (clinicaltrials.gov) - Mar 20, 2018
P2, N=99, Not yet recruiting, Sponsor: Fundacion CRIS de Investigaci
- | Phase classification, Trial completion date: Primary Breast Cancer Occurring Concomitant With Pregnancy (clinicaltrials.gov) - Mar 16, 2018
P1, N=100, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2023 --> Mar 2024 Phase classification: P=N/A --> P1 | Trial completion date: Aug 2019 --> Aug 2020
- ||| New P1 trial, Combination therapy: NP40126: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL (clinicaltrials.gov) - Mar 15, 2018
P1b, N=172, Recruiting, Sponsor: Hoffmann-La Roche
- | Enrollment closed, Enrollment change: CHEMO-T: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study (clinicaltrials.gov) - Mar 15, 2018
P2, N=87, Active, not recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Phase classification: P=N/A --> P1 | Trial completion date: Aug 2019 --> Aug 2020 Recruiting --> Active, not recruiting | N=186 --> 87
- | carboplatin / Generic mfg.
Trial completion date, Trial primary completion date: Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) (clinicaltrials.gov) - Mar 15, 2018
P3, N=840, Recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting | N=186 --> 87 Trial completion date: Jun 2023 --> Mar 2023 | Trial primary completion date: Dec 2018 --> Mar 2023
- | Rituxan (rituximab) / Roche
Enrollment closed: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 14, 2018
P2, N=53, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial completion date: Jun 2023 --> Mar 2023 | Trial primary completion date: Dec 2018 --> Mar 2023 Terminated --> Active, not recruiting